Page 13 - JCTR-10-6

Hanno et al.ǀ Journal of Clinical and Translational Research 2024; 10(6): 317-324 323
[18] Scarpignato C, Hunt RH. Acid suppressant therapy: A doi: 10.15415/mjis.2014.31005
step forward with potassium-competitive acid blockers. [27] Fallone CA, Chiba N, Van Zanten SV, Fischbach L,
Curr Treat Options Gastroenterol 2021;19:94-132. Gisbert JP, Hunt RH, et al. The toronto consensus for
doi: 10.1007/s11938-020-00330-x the treatment of Helicobacter pylori infection in adults.
[19] Graham DY, Lu H, Shiotani A. Vonoprazan-containing Gastroenterology 2016;151:51-69.
Helicobacter pylori triple therapies contribution to doi: 10.1053/j.gastro.2016.04.006
global antimicrobial resistance. J Gastroenterol Hepatol [28] Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP,
2021;36:1159-63. Kuipers E, Axon A, et al. Management of Helicobacter
doi: 10.1111/jgh.15252 pylori infection-the Maastricht V/florence consensus
[20] Matsukawa J, Hori Y, Nishida H, Kajino M, Inatomi N. report. Gut 2017;66:6-30.
A comparative study on the modes of action of TAK-438, doi: 10.1136/gutjnl-2016-312288
a novel potassium-competitive acid blocker, and [29] Kim BJ, Yang CH, Song HJ, Jeon SW, Kim GH,
lansoprazole in primary cultured rabbit gastric glands. Kim HS, et al. Online registry for nationwide database
Biochem Pharmacol 2011;81:1145-51. of Helicobacter pylori eradication in Korea: Correlation
doi: 10.1016/j.bcp.2011.02.009 of antibiotic use density with eradication success.
[21] Hori Y, Matsukawa J, Takeuchi T, Nishida H, Kajino M, Helicobacter 2019;24:e12646.
Inatomi N. A study comparing the antisecretory effect of doi: 10.1111/hel.12646
TAK-438, a novel potassium-competitive acid blocker, [30] Liou JM, Fang YJ, Chen CC, Bair MJ, Chang CY, Lee YC,
with lansoprazole in animals. J Pharmacol Exp Ther et al. Concomitant, bismuth quadruple, and 14-day triple
2011;337:797-804. therapy in the first-line treatment of Helicobacter pylori:
doi: 10.1124/jpet.111.179556 A multicentre, open-label, randomised trial. Lancet
[22] Sakurai Y, Nishimura A, Kennedy G, Hibberd M, 2016;388:2355-65.
Jenkins R, Okamoto H, et al. Safety, tolerability, doi: 10.1016/S0140-6736(16)31409-X
pharmacokinetics, and pharmacodynamics of single [31] Fiorini G, Zullo A, Saracino IM, Gatta L, Pavoni M,
rising TAK-438 (Vonoprazan) doses in healthy Vaira D. Pylera and sequential therapy for first-line
male Japanese/non-Japanese subjects. Clin Transl Helicobacter pylori eradication: A culture-based study
Gastroenterol 2015;6:e94. in real clinical practice. Eur J Gastroenterol Hepatol
doi: 10.1038/ctg.2015.18 2018;30:621-5.
[23] Jenkins H, Sakurai Y, Nishimura A, Okamoto H, doi: 10.1097/MEG.0000000000001102
Hibberd M, Jenkins R, et al. Randomised clinical [32] McNicholl AG, Marin AC, Molina-Infante J, Castro M,
trial: Safety, tolerability, pharmacokinetics and Barrio J, Ducons J, et al. Randomised clinical trial
pharmacodynamics of repeated doses of TAK-438 comparing sequential and concomitant therapies for
(vonoprazan), a novel potassium-competitive acid Helicobacter pylori eradication in routine clinical
blocker, in healthy male subjects. Aliment Pharmacol practice. Gut 2014;63(2):244-9.
Ther 2015;41:636-48. doi: 10.1136/gutjnl-2013-304820
doi: 10.1111/apt.13121 [33] Ozaki H, Harada S, Takeuchi T, Kawaguchi S,
[24] Murakami K, Sakurai Y, Shiino M, Funao N, Takahashi Y, Kojima Y, et al. Vonoprazan, a novel
Nishimura A, Asaka M. Vonoprazan, a novel potassium- potassium-competitive acid blocker, should be used
competitive acid blocker, as a component of first-line for the Helicobacter pylori eradication therapy as first
and second-line triple therapy for Helicobacter pylori choice: A large sample study of vonoprazan in real world
eradication: A phase III, randomised, double-blind study. compared with our randomized control trial using second-
Gut 2016;65:1439-46. generation proton pump inhibitors for Helicobacter
doi: 10.1136/gutjnl-2015-311304 pylori eradication therapy. Digestion 2018;97(3):212-8.
[25] Malfertheiner P, Bazzoli F, Delchier JC, Celiñski K, doi: 10.1159/000485097
Giguère M, Rivière M, et al. Helicobacter pylori [34] Sakurai Y, Mori Y, Okamoto H, Nishimura A, Komura E,
eradication with a capsule containing bismuth subcitrate Araki T, et al. Acid-inhibitory effects of vonoprazan
potassium, metronidazole, and tetracycline given with 20 mg compared with esomeprazole 20 mg or rabeprazole
omeprazole versus clarithromycin-based triple therapy: 10 mg in healthy adult male subjects--a randomised
A randomised, open-label, non-inferiority, phase 3 trial. open-label cross-over study. Aliment Pharmacol Ther
Lancet 2011;377:905-13. 2015;42:719-30.
doi: 10.1016/S0140-6736(11)60020-2 doi: 10.1111/apt.13325
[26] Muralidharan K. On sample size determination. Math J [35] Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E.
Interdiscip Sci 2014;3:55-64. Prevalence of antibiotic resistance in Helicobacter

DOI: http://doi.org/10.36922/jctr.24.00043